B+
Bull case
0%
Probability
Target price
$56.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
EXEL
ExelixisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q1 print showed continued cabozantinib franchise growth, with net product revenue up year over year on volume, while management kept 2026 guidance unchanged and reiterated a dense zanzalintinib milestone calendar. Post-earnings target increases from Morgan Stanley, Stifel, TD Cowen, and H.C.
Posture
Defensive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Cabozantinib still accounts for the majority of revenue, leaving the story exposed to single-franchise concentration risk [#10-Q-2026-05-05].
Momentum
51
Value
68
Sentiment
43
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $48.00 · Bull $56.00 · Bear $39.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $53.69
Why
Momentum51 · Δ7d +19.0
Value68 · Δ7d -0.0
Sentiment43 · Δ7d +3.5
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +3.5.
Contradictions & invalidation
- • Cabozantinib still accounts for the majority of revenue, leaving the story exposed to single-franchise concentration risk [#10-Q-2026-05-05].
- • Pipeline timing and readout risk remain high across STELLAR-303, STELLAR-304, STELLAR-311, and STELLAR-316; delays or mixed data would pressure the current pipeline premium [#8-K-2026-05-05].
- • The stock remains dependent on cabozantinib for the majority of revenue and the maintained 2026 outlook explicitly excludes any U.S.
Catalyst clock
2026-05-31
Post-earnings execution and capital return follow-through
Lead driver: Sentiment · See AI snapshot
Momentum
51
9% active weight
Current posture
7d trendImproving
Δ7d
+19.0
Δ21d
+14.0
Value
68
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.4
Sentiment
43
62% active weight
Current posture
7d trendImproving
Δ7d
+3.5
Δ21d
-7.1
Why this grade
Composite grade D. Momentum 51.2 / Value 67.5 / Sentiment 43.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$12.96B
Beta
0.42
Shares Out
247.78M
P/E (TTM)
17.9
P/S (TTM)
4.97
P/FCF (TTM)
14.58
Rev YoY
+10.6%
EPS YoY
+25.6%
Gross Margin
+96.5%
Op Margin
+40.7%
Net Debt
-$858.17M
Current Ratio
3.46
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data